Russell Harmony, NP
Interventional Pain Medicine · Meridian, IDNPI 1194065730
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (37.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Abbott accounts for 95.3% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $11,273 and has fallen 93.7% since, to $712 in 2025.
Across 195 payments — averaging $89.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$17K
- Averitas Pharma Inc.$537
- Boston Scientific$264
- Vertex$20
What the payments were for
- Consulting fees$2501%
- Speaking & faculty fees$6,54838%
- Travel & lodging$6,19836%
- Food & beverage$4,43225%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 157 | $16,607 |
| Averitas Pharma Inc. | 25 | $537 |
| Boston Scientific | 12 | $264 |
| Vertex | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few interventional pain medicine providers in Idahoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 685 | $21,301 |
| Fentanyl | 41 | $15,485 |
| Hydromorphone ErHydromorphone Hcl | 43 | $13,711 |
| Pregabalin | 206 | $8,881 |
| Emgality PenGalcanezumab-Gnlm | 12 | $7,822 |
| OxycontinOxycodone Hcl | 15 | $7,258 |
| Buprenorphine | 20 | $6,933 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 222 | $5,648 |
| Gabapentin | 190 | $4,854 |
| Morphine Sulfate ErMorphine Sulfate | 132 | $3,448 |
| Celecoxib | 33 | $2,460 |
| Lidocaine | 24 | $2,335 |
| Tramadol Hcl ErTramadol Hcl | 24 | $2,083 |
| Oxycodone Hcl | 109 | $1,802 |
| Tramadol Hcl | 177 | $1,697 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Meridian
- Shane MaxwellMeridian$6K
- Karl ZarseMeridian$6K
- John HathewayCoeur D Alene$800K
- Craig FlindersLewiston$13K
- Lyndal StoutinLewiston$3K
- Christian BeckerIdaho Falls$66
- Patrick FarrellBoise$15
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.